| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 10/25/2001 | WO2001079524A2 Tissue-specific and pathogen-specific toxic agents, ribozymes, dnazymes and antisense oligonucleotides, and methods of use thereof |
| 10/25/2001 | WO2001079520A1 Hybrid glycosylated products and their production and use |
| 10/25/2001 | WO2001079502A2 Vectors for gene therapy |
| 10/25/2001 | WO2001079469A2 Cloning of corynebacteriaceae histidine ammonia lyase and therapeutic uses |
| 10/25/2001 | WO2001079302A1 A complex between folic acid and polysaccharides, its preparation method and a pharmaceutical composition comprising said complex as active component |
| 10/25/2001 | WO2001079284A2 Therapeutic compounds and methods for formulating v3, a versican isoform |
| 10/25/2001 | WO2001079253A1 Extracellular matrix polynucleotides, polypeptides, and antibodies |
| 10/25/2001 | WO2001079247A1 Novel discalamide compounds and their use as anti-proliferative agents |
| 10/25/2001 | WO2001079246A2 3'-or 2'-hydroxymethyl substituted nucleoside derivatives for treatment of hepatitis virus infections |
| 10/25/2001 | WO2001079245A1 Novel flavone glycoside derivatives for use in cosmetics, pharmaceuticals and nutrition |
| 10/25/2001 | WO2001079244A1 Pharmaceutical dopamine glycoconjugate compositions and methods of their preparation |
| 10/25/2001 | WO2001079243A1 Glycosides of n-acetyl-6-o-[2,2-bis(hydroxymethyl)-3-hydroxypropyl]-d-glucosamine, method for the obtention thereof and their uses in the treatment of brain tumors |
| 10/25/2001 | WO2001079212A1 Silicon derivatives of fragrant, flavouring and medicinal substances |
| 10/25/2001 | WO2001079211A1 Process for the preparation of a 3-vinylcephem compound |
| 10/25/2001 | WO2001079202A1 Processes for the preparation of thiazolidinedione derivatives and intermediates |
| 10/25/2001 | WO2001079198A1 Pyrazoles for inhibiting protein kinase |
| 10/25/2001 | WO2001079197A1 ACTIVATORS FOR PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR δ (PPARδ) |
| 10/25/2001 | WO2001079196A2 1-(h-1,2,4-triazol-1-yl)butan-2-ol derivatives |
| 10/25/2001 | WO2001079180A2 5-substituted tetralones as inhibitors of ras farnesyl transferase |
| 10/25/2001 | WO2001079179A2 Dihydro-2h-naphthalene-1-one inhibitors of ras farnesyl transferase |
| 10/25/2001 | WO2001079173A2 Enamine derivatives as cell adhesion molecules |
| 10/25/2001 | WO2001079172A1 Vitronectin receptor antagonist bicyclic compounds, preparation method and compositions containing same |
| 10/25/2001 | WO2001079170A2 Aminophenoxyacetamide derivatives and pharmaceutical composition containing thereof |
| 10/25/2001 | WO2001079167A2 Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis |
| 10/25/2001 | WO2001079164A2 N-substituted dithiocarbamates for the treatment of biological disorders |
| 10/25/2001 | WO2001079158A2 Compounds for modulating cell proliferation |
| 10/25/2001 | WO2001079157A1 Hydrazide and alkoxyamide angiogenesis inhibitors |
| 10/25/2001 | WO2001079156A1 Halogenated 2-amino-4, 5 heptenoic acid derivatives useful as nitric oxide synthase inhibitors |
| 10/25/2001 | WO2001079155A2 Polycyclic aryl and heteroaryl substituted 1,4-quinones useful for selective inhibition of the coagulation cascade |
| 10/25/2001 | WO2001079153A1 Compounds, compositions and methods for preventing neurodegeneration in acute and chronic injuries in the central nervous system |
| 10/25/2001 | WO2001079150A1 New compounds, their preparation and use |
| 10/25/2001 | WO2001078803A1 Systems, kits, and methods of administering synthetic plasma |
| 10/25/2001 | WO2001078784A1 Aqueous-prodrug compound comprising moiety of paclitxel or derivatives thereof, method of preparing same and pharmaceutical composition comprising same |
| 10/25/2001 | WO2001078782A1 Single-dose antihistamine/decongestant formulations for treating rhinitis |
| 10/25/2001 | WO2001078781A2 Methods for prevention and treatment of gastrointestinal disorders |
| 10/25/2001 | WO2001078779A2 Antibody alpha4beta7 integrin and its use to treat inflammatory bowel disease |
| 10/25/2001 | WO2001078771A1 Method of preventing or treating diabetes |
| 10/25/2001 | WO2001078761A2 Mixture of defibrotide and g-csf ant its use for activating haematopoietic progenitors |
| 10/25/2001 | WO2001078749A1 Novel calcium antagonists |
| 10/25/2001 | WO2001078748A2 Immunomodulatory methods using carbohydrate antigens |
| 10/25/2001 | WO2001078747A1 Use of cse inhibitors for treating heart failure |
| 10/25/2001 | WO2001078746A1 Respiratory compositions |
| 10/25/2001 | WO2001078745A1 Medical combinations comprising formoterol and fluticasone proprionate |
| 10/25/2001 | WO2001078744A1 Medical combinations comprising formoterol and mometasone |
| 10/25/2001 | WO2001078743A1 Medical combinations comprising tiotropium and mometasone |
| 10/25/2001 | WO2001078742A1 Medical combination comprising salmeterol and budesonide |
| 10/25/2001 | WO2001078741A1 Medical combinations comprising tiotropium and budesonide |
| 10/25/2001 | WO2001078740A1 Medical combinations comprising mometasone and salmeterol |
| 10/25/2001 | WO2001078739A1 Medical combinations comprising tiotropium and fluticasone proprionate |
| 10/25/2001 | WO2001078738A1 Medical compositions comprising (r,r)-formoterol and rofleponide |
| 10/25/2001 | WO2001078737A1 Medical combinations comprising formoterol and budesonide |
| 10/25/2001 | WO2001078736A1 Medical combinations comprising tiotropium and rofleponide |
| 10/25/2001 | WO2001078735A1 Medicaments for treating respiratory disorders comprising formoterol and fluticasone |
| 10/25/2001 | WO2001078734A1 Methods of treatment |
| 10/25/2001 | WO2001078733A1 Alpha,beta-unsaturated sulfones for treating proliferative disorders |
| 10/25/2001 | WO2001078732A1 Ciprofloxacin infusion solutions having a good storage stability |
| 10/25/2001 | WO2001078731A1 Ciprofloxacin infusion solutions with improved storage life |
| 10/25/2001 | WO2001078730A1 Methods and compositions useful in enhancing oxygen delivery to cells |
| 10/25/2001 | WO2001078729A1 Method of dopamine inhibition using l-threo-methylphenidate |
| 10/25/2001 | WO2001078728A1 Acetylcholinesterase inhibitors containing 1-benzyl- pyridinium salts |
| 10/25/2001 | WO2001078727A1 Topical formulations for the transdermal delivery of niacin and methods of treating hyperlipidemia |
| 10/25/2001 | WO2001078726A1 New uses of imidazolylmethyl-pyridines |
| 10/25/2001 | WO2001078725A2 Modified release formulations containing a hypnotic agent |
| 10/25/2001 | WO2001078724A1 Rapid-onset formulation of a selective cyclooxigenase-2 |
| 10/25/2001 | WO2001078723A1 Compounds and methods |
| 10/25/2001 | WO2001078722A1 Pharmaceutical compositions containing 5-hydroxyoxindole and use thereof |
| 10/25/2001 | WO2001078721A1 Aβ42 LOWERING AGENTS |
| 10/25/2001 | WO2001078720A1 Decreasing the intracellular level of beta-catenin by administering hydroxymatairesinol |
| 10/25/2001 | WO2001078719A1 Halogentated 2-amino-5,6 heptenoic acid derivatives useful as nitric oxide synthase inhibitors |
| 10/25/2001 | WO2001078718A1 Methods of use of penicillamines for the treatment of conditions resulting from dna damage |
| 10/25/2001 | WO2001078717A1 Pharmacotherapy for vascular dysfunction associated with deficient nitric oxide bioactivity |
| 10/25/2001 | WO2001078716A1 Solid dispersion with improved absorbability |
| 10/25/2001 | WO2001078715A1 Method of treating alzheimer's disease |
| 10/25/2001 | WO2001078713A1 Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use |
| 10/25/2001 | WO2001078712A1 Substituted styryl benzylsulfones for treating proliferative disorders |
| 10/25/2001 | WO2001078711A2 Pde-v inhibitors for treatment of parkinson's disease |
| 10/25/2001 | WO2001078710A2 Paclitaxel treatment regimen for metastatic melanoma |
| 10/25/2001 | WO2001078709A2 Treatment of neurodegenerative disease |
| 10/25/2001 | WO2001078708A1 Treating graft rejection with cxcr3 inhibitors |
| 10/25/2001 | WO2001078707A1 Treating graft rejection with ccr5 inhibitors |
| 10/25/2001 | WO2001078706A2 Treatment of hyperproliferative, inflammatory and related mucocutaneous disorders using inhibitors of mevalonate synthesis and metabolism |
| 10/25/2001 | WO2001078705A2 Compositions containing a naphthalmide and an antiproliferative agent |
| 10/25/2001 | WO2001078704A2 Gaba substrate and the use thereof for treating cognitive and emotional disorders |
| 10/25/2001 | WO2001078703A2 Methods and compositions for modulating alpha adrenergic receptor activity |
| 10/25/2001 | WO2001078702A2 Methods and compositions for modulating alpha adrenergic receptor activity |
| 10/25/2001 | WO2001078701A2 Method and compositions for preventing hormone induced adverse effects |
| 10/25/2001 | WO2001078700A2 Compositions for use in modulating immune system function comprising at least one retrinoid and at least one cytokine |
| 10/25/2001 | WO2001078699A2 Use of bradycardiac substances in the treatment of myocardial diseases associated with hypertrophy and novel medicament combinations |
| 10/25/2001 | WO2001078698A2 Use of ngf-antagonists for the prevention or treatment of chronic visceral pain |
| 10/25/2001 | WO2001078697A2 Method and compositions for the treatment of allergic conditions using pgd2 receptor antagonists |
| 10/25/2001 | WO2001078696A2 Formulations for use in inhaler devices |
| 10/25/2001 | WO2001078695A2 Pharmaceutical formulations for dry powder inhalers |
| 10/25/2001 | WO2001078694A2 Formulations for use in inhaler devices |
| 10/25/2001 | WO2001078693A2 Pharmaceutical formulations for dry powder inhalers in the form of hard-pellets |
| 10/25/2001 | WO2001078692A2 Membrane delivery system |
| 10/25/2001 | WO2001078690A1 Patch containing anti-inflammatory agent |
| 10/25/2001 | WO2001078688A1 Hydrophilic/lipophilic polymeric matrix dosage formulation |
| 10/25/2001 | WO2001078686A1 Time-release coated solid compositions for oral administration |
| 10/25/2001 | WO2001078685A1 A method of inducing or enhancing chondrogenesis with extracellular matrix containing bmp-4 |
| 10/25/2001 | WO2001078683A2 Sustained release formulations comprising growth hormone |